Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CRBP |
---|---|---|
09:32 ET | 669 | 17.64 |
09:33 ET | 113 | 17.6744 |
09:35 ET | 300 | 17.92 |
09:42 ET | 300 | 17.805 |
09:44 ET | 200 | 17.765 |
09:46 ET | 476 | 17.7 |
09:48 ET | 500 | 17.72 |
09:53 ET | 111 | 17.64 |
09:57 ET | 282 | 17.655 |
10:00 ET | 906 | 17.4963 |
10:02 ET | 100 | 17.5325 |
10:04 ET | 300 | 17.66 |
10:06 ET | 100 | 17.64 |
10:09 ET | 100 | 17.73 |
10:11 ET | 700 | 17.74 |
10:13 ET | 607 | 17.8 |
10:15 ET | 708 | 17.87 |
10:18 ET | 219 | 17.76 |
10:20 ET | 361 | 17.7001 |
10:22 ET | 100 | 17.755 |
10:24 ET | 200 | 17.7 |
10:26 ET | 100 | 17.77 |
10:27 ET | 100 | 17.82 |
10:33 ET | 247 | 17.78 |
10:36 ET | 100 | 17.84 |
10:38 ET | 100 | 17.815 |
10:42 ET | 856 | 17.7108 |
10:44 ET | 2877 | 17.765 |
10:49 ET | 508 | 17.8 |
10:51 ET | 200 | 17.84 |
10:56 ET | 100 | 17.81 |
10:58 ET | 2887 | 17.92 |
11:00 ET | 480 | 17.94 |
11:05 ET | 100 | 17.86 |
11:07 ET | 300 | 17.9 |
11:14 ET | 100 | 17.82 |
11:18 ET | 300 | 17.76 |
11:25 ET | 300 | 17.89 |
11:34 ET | 300 | 17.88 |
11:36 ET | 200 | 17.76 |
11:39 ET | 100 | 17.84 |
11:41 ET | 155 | 17.81 |
11:43 ET | 100 | 17.84 |
11:48 ET | 100 | 17.825 |
11:50 ET | 300 | 17.9 |
11:52 ET | 2589 | 17.95 |
11:56 ET | 255 | 17.9089 |
11:59 ET | 452 | 17.895 |
12:03 ET | 240 | 17.87 |
12:06 ET | 250 | 17.865 |
12:10 ET | 100 | 17.915 |
12:14 ET | 400 | 17.9 |
12:15 ET | 700 | 17.92 |
12:19 ET | 200 | 17.84 |
12:28 ET | 100 | 17.88 |
12:35 ET | 300 | 17.92 |
12:44 ET | 500 | 17.95 |
12:46 ET | 520 | 18.01 |
12:50 ET | 300 | 17.975 |
12:51 ET | 600 | 17.89 |
12:53 ET | 573 | 17.91 |
12:55 ET | 813 | 17.885 |
12:57 ET | 4093 | 17.865 |
01:00 ET | 29938 | 17.82 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Corbus Pharmaceuticals Holdings Inc | 214.8M | -3.8x | --- |
Compass Therapeutics Inc. | 214.6M | -4.6x | --- |
TuHURA Biosciences Inc | 213.5M | -0.5x | --- |
Climb Bio Inc | 216.5M | -1.5x | --- |
Trevi Therapeutics Inc | 216.8M | -6.5x | --- |
Kyverna Therapeutics Inc | 218.4M | -2.3x | --- |
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $214.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 12.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.58 |
EPS | $-4.69 |
Book Value | $-1.56 |
P/E Ratio | -3.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.